

Journal of *In Silico* and *In Vitro* Pharmacology is Welcoming Authors for Submissions of a Manuscript

Received: January 01, 2021; Accepted: January 14, 2021; Published: January 21, 2021

Announcement

First and foremost, we'd want to thank the Open Access Journal's reviewers and writer for their efforts. Many famous scholars collaborate with the Journal of *In Silico* and *In vitro* Pharmacology to provide high-quality publications in the field of Pharmacology.

To maintain uniformity in the peer-review process, we use an Editorial Tracking System, which is an online manuscript submission, analysis, and tracking system. Each citable submission must be examined by at least two independent reviewers before being approved by the publisher and review processing is done by members of the Journal's editorial board or outside experts.

We are immensely appreciative for our board members' invaluable contributions to both our rigorous companion audit methodology and the Journey's vital growth. As everyone knows, Reviewer Board Members play a critical role in fostering the reviewers' aim to maintain the highest possible standards of informative excellence in the work we provide.

The Journal community is made up of global experts in similar logical distributions. All submitted papers go through various processes to ensure uniformity in delivery. The compositions are audited in the same way that other documents are. The endless supply of paper is a good place to start when screening. In any instance, two free references are included with the appropriate articles.

The COVID-19 outbreak has caused broad disruption, providing issues for everyone. While dealing with the influence of this pandemic ailment on their day-to-day life, several researchers/technicians are also dealing with concerns such as laboratory closures and the arrangement of online education. Many of the writers, reviewers, and publishers who work for a variety of magazines are still practising physicians. As a result, delays are unavoidable during this pandemic period, and we appreciate your patience. It's critical that our Editors and Editorial Advisory Board debate the issues we distribute and represent the countries from

Alessia D'souza*

Editorial Office, Journal of *In silico* and *In vitro* pharmacology, London, UK

*Corresponding author: Alessia D'souza

✉ invitropharma@jopenaccess.org

Editorial Office, Journal of *In silico* and *In vitro* pharmacology, London, UK.

Citation: D'souza A (2021) Journal of *In Silico* and *In Vitro* Pharmacology is Welcoming Authors for Submissions of a Manuscript. *In Silico In Vitro Pharmacol* Vol.7 No.1:4

which our submissions originate. Furthermore, pharmacology is a discipline of science that studies medications and their effects on living organisms. In this way the drugs work in the body.

The goal of the Journal of *in silico* and *in vitro* Pharmacology is to bridge the gap between molecular modelling and *in silico* pharmacological methodologies for drug development. It explains how to use these models in the discovery and optimization of novel molecules for a target, as well as the clarification of absorption, distribution, metabolism, and elimination, all of which are referred to as pharmacokinetics and toxicity properties, and physicochemical characterization.

Researchers, scientists, and authors are urged to submit material that is relevant to the scope of this journal. We offer a high-quality and quick review service. As a result, authors are encouraged to submit original research papers. Review papers are especially encouraged. However, because the Special Issue will also contain a number of invited reviews, review papers should be discussed with the Editors early on to minimise duplication.

You can submit a manuscript, a research article, a mini review, a commentary, a case report, or anything else. Manuscripts should be sent to the Editorial Office as an E-mail attachment to invitropharma@jopenaccess.org.